|
- AstraZeneca | Cafepharma
AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
- AstraZeneca | Cafepharma
AstraZeneca’s quarterly revenue crossed the $15-billion mark for the first time, giving renewed hope to the company's target of reaching $80 billion in annual sales by the end of the decade "The strong underlying momentum across our business…sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition," remarked CEO Pascal Soriot on Thursday
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca
- AstraZenecas latest amyloidosis pact with Neurimmune could reach $780M . . .
Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset The latest licensing deal involves NI009, a preclinical monoclonal antibody that targets lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis In return for the exclusive rights, AstraZeneca’s Alexion
- AstraZenecas Fasenra (benralizumab) Fails Ph III Trial for COPD
AstraZeneca and MedImmune, announced on 5 11 18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD
- July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in . . .
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapiesNovartis boardHow Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
- Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous board for Pfizer
- CMO | Cafepharma
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M D , to leave the Anglo-Swedish drugmaker and take responsibility of all its product development
|
|
|